In Chapel Hill, North Carolina, researchers at UNC School of Medicine have identified a molecular target that could fundamentally shift how doctors treat one of the blood's most aggressive cancers—a discovery that arrives as a lifeline for patients whose tumors relentlessly evade existing therapies.
The cancer is non-Hodgkin lymphoma (NHL), and the virus behind it is Epstein-Barr, the same common pathogen responsible for mononucleosis. EBV-positive NHL carries sobering odds: a lifetime risk of 1 in 46 for men and roughly 1 in 55 for women. But what makes this particular cancer especially difficult to treat is its ability to develop resistance with startling speed. Patients whose lymphomas learn to outsmart one therapy find themselves with few alternatives, and outcomes can be dire.
Now, a team led by Blossom Damania, Ph.D. at UNC Lineberger Comprehensive Cancer Center has pinpointed a vulnerability in these resistant tumors. The culprit is an enzyme called NEK2, which drives cancer cell division and proliferation. In aggressive lymphomas, NEK2 levels soar—so high, in fact, that doctors now recognize it as a biomarker of poor prognosis. The question became irresistible: What if researchers could shut it down?
Maria White, Ph.D., a postdoctoral researcher in the Damania lab and lead author of the new study published in the Proceedings of the National Academy of Sciences, put that question to the test. When White and her team selectively inactivated NEK2 in cancer cell models, something promising happened. Some lymphoma cells died outright. Others became sensitized—made vulnerable to companion anti-cancer treatments that might otherwise fail. Crucially, when they switched off NEK2, non-cancerous cells remained unharmed, suggesting the approach could spare healthy tissue from collateral damage, a persistent problem in cancer medicine.
The real validation came in preclinical models. When researchers tested NEK2 inhibitors in live animals with EBV-associated NHL, survival extended measurably. Tumor burden dropped throughout the body. In a handful of cases, all observable traces of lymphoma vanished completely—a result that, while preliminary, hints at genuine therapeutic promise.
"Many EBV-positive lymphomas can rapidly develop resistance to treatment, leading to poor patient outcomes," White noted in reflecting on the research. "Our research indicates that targeting a single enzyme may offer a more effective approach for the treatment of EBV-positive NHL."
That shift—from fighting a moving target to attacking a fixed vulnerability—could reshape outcomes for thousands of patients. The work remains in its preclinical phase, and the leap from laboratory success to human treatment is never guaranteed. Yet the clarity of the mechanism and the durability of the effect across multiple experimental systems suggest the pathway is worth pursuing. The team's next steps include moving NEK2 inhibitors into clinical trials, where the real test of whether this laboratory insight can translate into lives saved will begin. For patients with EBV-positive NHL, that prospect carries genuine weight.